Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NARB Upholds NAD Recommendations For Colgate Sensitive Ads

This article was originally published in The Tan Sheet

Executive Summary

The Council of Better Business Bureaus appeals board agrees that testing does not support claims that Colgate Sensitive Pro-Relief is “faster” and “better” than GlaxoSmithKline's Sensodyne. Colgate argued its studies were sufficient, having incorporated industry-standard methodology accepted by FDA and the ADA.

You may also be interested in...



Sensodyne's 'Recommended' Claims Stick To The Point On Sensitivity – NAD

GSK does not need to qualify “#1 Dentist Recommended Brand” claim on packaging and online ads because consumers do not mistakenly understand it to apply to the general toothpaste market, industry self-regulation form says on Colgate challenge.

In Brief

Health Canada warns of benzocaine risk; Perrigo first with store-brand Mucinex; NAD enters Glaxo/Colgate toothpaste war; Sun Capital snags supplement manufacturer CornerStone; more news In Brief.

Firmenich, IFF Tout Eco-Fragrance Design Tools; Inter Parfums’ Sales Soar In Q4; Fragrance Sales & Sustainability News

Firmenich and International Flavors & Fragrances’ LRM Naturals announce developments to better support customers’ sustainable product development and transparency needs. Givaudan, Symrise and Inter Parfums report strong results in fiscal 2022, fueled by unleashed fragrance demand around the globe.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105992

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel